Skip to main content

Advertisement

SpringerLink
Log in

Mycophenolate mofetil in juvenile dermatomyositis: a case series

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The objective of this study was to report the use of Mycophenolate Mofetil (MMF) in Juvenile Dermatomyositis (JDM). A retrospective chart review of children diagnosed with JDM having received MMF was performed. Response was evaluated 3 months after the onset of MMF by comparing muscle strength and steroid dosage before and after treatment. A good response was defined by global improvement concerning weakness and fatigability as evaluated subjectively by the physician along with a gain of at least 4 points on each of 2 muscle testings (Manual Muscle Testing, MMT and Childhood Myositis Assessment Score, CMAS) and/or a decrease of >15% of the corticosteroid dosage. Eight patients were identified. Except for one, all had received MMF secondary to an initial therapy of conventional immunosuppressants. Six patients showed good response by our predefined criteria. Changes of muscle testing scores ranged between +0 to +21 points (mean = +10.6) for the MMT and between +3 and +11 (mean = +7) for the CMAS. Corticosteroid tapering varied from 0 to 50%, with a mean of 18%. In most cases, follow-up was available for many months (up to 26); overall, we observed only one complication: a transient neutropenia in a patient concurrently receiving another immunosuppressant. This small series is the first published report on the use of MMF in JDM and suggests it is safe. Prospective larger studies are required to further elucidate the use of MMF in JDM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Pachman LM (1994) Juvenile dermatomyositis (JDMS): new clues to diagnosis and pathogenesis. Clin Exp Rheumatol 12(Suppl 10):S69–S73

    PubMed  Google Scholar 

  2. Mendez EP, Lipton R, Ramsey-Goldman R et al (2003) US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 49(3):300–305

    Article  PubMed  Google Scholar 

  3. Stringer E, Feldman BM (2006) Advances in the treatment of juvenile dermatomyositis. Curr Opin Rheumatol 18(5):503–506

    Article  PubMed  Google Scholar 

  4. Zwerner J, Fiorentino D (2007) Mycophenolate mofetil. Dermatol Ther 20(4):229–238

    Article  PubMed  Google Scholar 

  5. Iaccarino L, Arienti S, Rampudda M et al (2007) Mycophenolate mofetil in lupus glomerulonephritis: effectiveness and tolerability. Ann N Y Acad Sci 1110:516–524

    Article  PubMed  CAS  Google Scholar 

  6. Iaccarino L, Rampudda M, Canova M et al (2007) Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev 6(3):190–195

    Article  PubMed  CAS  Google Scholar 

  7. Falcini F, Capannini S, Martini G et al (2009) Mycophenolate mofetil for the treatment of juvenile onset SLE: a multicenter study. Lupus 18(2):139–143

    Article  PubMed  CAS  Google Scholar 

  8. Edge JC, Outland JD, Dempsey JR, Callen JP (2006) Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 142(1):65–69

    Article  PubMed  CAS  Google Scholar 

  9. Rowin J, Amato AA, Deisher N et al (2006) Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 66(8):1245–1247

    Article  PubMed  CAS  Google Scholar 

  10. Danieli MG, Calcabrini L, Calabrese V et al (2009) Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev 9(2):124–127

    Article  PubMed  CAS  Google Scholar 

  11. Ruperto N, Ravelli A, Pistorio A et al (2008) The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 59(1):4–13

    Google Scholar 

  12. Isenberg DA, Allen E, Farewell V et al (2004) International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43(1):49–54

    Article  CAS  Google Scholar 

  13. Dawkins MA, Jorizzo JL, Walker FO et al (1998) Dermatomyositis: a dermatology-based case series. J Am Acad Dermatol 38(3):397–404

    Article  PubMed  CAS  Google Scholar 

  14. Dauden E, Sanchez-Peinado C, Ruiz-Genao D et al (2004) Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis. Br J Dermatol 150(1):132–135

    Article  PubMed  CAS  Google Scholar 

  15. Filler G, Hansen M, LeBlanc C et al (2003) Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatr Nephrol 18(5):445–449

    PubMed  Google Scholar 

  16. Macedo PA, Garcia CB, Schmitz MK et al (2010) Juvenile systemic lupus erythematosus and dermatomyositis associated with urticarial vasculitis syndrome: a unique presentation. Rheumatol Int. doi:10.1007/s00296-010-1484-4

Download references

Note added in proof

After submission of the manuscript, a paper has been published in October 2010, suggesting that the use of MMF decreases skin and muscle disease activity and is steroid sparing in JDM [Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM (2010) Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res 62(10):1446–1451].

Author information

Authors and Affiliations

  1. University Hospital of Lyon, Femme-Mère-Enfant Hospital, Lyon, France

    Rawane Dagher, Marine Desjonquères, Agnès Duquesne, Pierre Quartier, Brigitte Bader-Meunier, Michel Fischbach, Vincent Guiguonis, Georges Picherot & Rolando Cimaz

Authors
  1. Rawane Dagher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marine Desjonquères
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Agnès Duquesne
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pierre Quartier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Brigitte Bader-Meunier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michel Fischbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Vincent Guiguonis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Georges Picherot
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rolando Cimaz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rawane Dagher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dagher, R., Desjonquères, M., Duquesne, A. et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int 32, 711–716 (2012). https://doi.org/10.1007/s00296-010-1653-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-010-1653-5

Keywords

Search

Navigation